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Abstract Aged (>50 years old) human immunodeficiency
virus (HIV) patients are the fastest-growing segment of the
HIV-infected population in the USA and despite antiretroviral
therapy, HIV-associated neurocognitive disorder (HAND)
prevalence has increased or remained the same among this
group. Autophagy is an intracellular clearance pathway for
aggregated proteins and aged organelles; dysregulation of
autophagy is implicated in the pathogenesis of Parkinson’s
disease, Alzheimer’s disease, and HAND. Here, we hypothe-
sized that dysregulated autophagy may contribute to aging-
related neuropathology in HIV-infected individuals. To ex-
plore this possibility, we surveyed autophagy marker levels
in postmortem brain samples from a cohort of well-
characterized <50 years old (young) and >50 years old
(aged) HIV+ and HIV encephalitis (HIVE) patients. Detailed
clinical and neuropathological data showed the young and
aged HIVE patients had higher viral load, increased neuro-
inflammation and elevated neurodegeneration; however, aged
HIVE postmortem brain tissues showed the most severe neu-
rodegenerative pathology. Interestingly, young HIVE patients
displayed an increase in beclin-1, cathepsin-D and light chain
(LC)3, but these autophagy markers were reduced in aged
HIVE cases compared to age-matched HIV+ donors. Similar
alterations in autophagymarkers were observed in aged gp120
transgenic (tg) mice; beclin-1 and LC3were decreased in aged
gp120 tg mice while mTor levels were increased. Lentivirus-
mediated beclin-1 gene transfer, that is known to activate
autophagy pathways, increased beclin-1, LC3, and
microtubule-associated protein 2 expression while reducing
glial fibrillary acidic protein and Iba1 expression in aged
gp120 tg mice. These data indicate differential alterations in
the autophagy pathway in young versus aged HIVE patients
and that autophagy reactivation may ameliorate the neurode-
generative phenotype in these patients.
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Introduction
Currently, over 30 million people live with human immu-
nodeficiency virus (HIV) worldwide. In the USA, the aging
population represents one of the fastest-growing groups
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with HIV (Scott et al. 2011). The Center for Disease Control
(CDC) estimates that by the year 2015, half of all Americans
living with HIV will be over the age of 50 (Smith 2005). In
the central nervous system (CNS), microglial cells have
been identified as a primary reservoir for HIV infection
(Gendelman et al. 1997; Gonzalez-Scarano and Martin-
Garcia 2005; Haas et al. 2000; Wiley et al. 1996) with
productive infection also detected in astrocytes (Carroll-
Anzinger and Al-Harthi 2006). Modern treatments with
highly active antiretroviral therapy regimens result in HIV
suppression and immune recovery, however the prevalence
of HIV-associated neurocognitive disorders (HAND) and
neurodegeneration (Budka et al. 1987; Cherner et al. 2007;
Gendelman et al. 1997; Heaton et al. 2010, 2011; Wiley and
Achim 1994) has remained the same or increased (Joska et
al. 2010) in particular among people over the age of 50.
The mechanisms of neurodegeneration in aged individu-
als with HAND are not completely understood; however,
HIV activates apoptotic pathways (Kaul et al. 2001), dysre-
gulates calcium homeostasis (Lipton 1994; Nath et al. 2000,
2002) and promotes oxidative stress (Norman et al. 2008).
Moreover, recent studies have shown that HIV proteins
might interfere with clearance pathways such as autophagy
(Alirezaei et al. 2008a, b; Zhou et al. 2011), a pathway
necessary for protein quality control and elimination of
defective older intracellular organelles (Cuervo 2004).
Autophagy is a complex process that involves nucleation,
initiation, elongation, and termination proteins. Initially, a
phagophore forms and develops into the autophagosome, a
double-membrane sac that delivers cytoplasmic material to
the lysosomal compartment for degradation (Codogno et al.
2012). During the aging process, deficits in autophagy have
been described in Alzheimer’s disease (AD; Nixon et al.
2005; Pickford et al. 2008), Parkinson’s disease (PD; Crews
et al. 2010; Cuervo et al. 2004), and other aging-related
disorders (Cuervo 2004). Specifically, the autophagy nucle-
ation protein beclin-1 and closure protein light chain (LC)3
have been implicated in human disease (Crews et al. 2010;
Gozuacik and Kimchi 2004; Jaeger and Wyss-Coray 2010).
Similarly, neurodegeneration has been linked to defects in
autophagy in patients with HIV (Alirezaei et al. 2008a, b;
Zhou et al. 2011).
We have recently shown that in the CNS of young HIV
human cases and in young transgenic (tg) mice expressing
HIV-gp120 protein (gp120 tg; Toggas et al. 1994), abnormal
functioning of the autophagy pathway (Zhou et al. 2011) is
associated with progressive accumulation of amyloid-beta
(Aβ; Achim et al. 2009), α-synuclein (α-syn; Ebrahimi-
Fakhari et al. 2011; Everall et al. 2009; Khanlou et al.
2009), and tau (Patrick et al. 2011). In contrast, activation
of autophagy by gene therapy recovers the deficits in
autophagy observed in α-syn tg mice (Spencer et al.
2009). However, the mechanisms by which HIV proteins
might interfere with autophagy during aging are unknown.
Here, we postulate that dysfunctional autophagy activity
may contribute to HAND progression in aged individuals.
In this report, we extend our past studies by characterizing
differences in viral load (VL), CNS immune activation and
expression of autophagy-related proteins among <50 years
old (young) and >50 years old (aged) HIV-infected individ-
uals. Our results indicate that while autophagy was upregu-
lated in the brains of young HIVE patients, it was
downregulated in the brains of aged HIVE patients.
Similarly, autophagy was downregulated in aged gp120 tg
mice and activation with beclin-1 gene transfer ameliorated
the neurodegenerative phenotype. These findings provide
novel insight and potentially important targets to combat
HAND in the aging population.
Methods
Study population
For the present study, we included a total of 83 HIV+ cases,
of which 50 are below 50 years and 33 are above 50 years
(Table 1) from the HIV Neurobehavioral Research Center
and California Neuro-Acquired Immunodeficiency
Syndrome (AIDS) Tissue Network at the University of
California, San Diego. Cases had neuromedical and neuro-
psychological examinations within a median of 12 months
before death. Most cases died as a result of acute broncho-
pneumonia or septicemia and autopsy was performed within
24 h of death. Autopsy findings were consistent with AIDS
and the associated pathology was most frequently due to
systemic cytomegalovirus (CMV), Kaposi sarcoma, and
liver disease. Subjects were excluded if they had a history
of CNS opportunistic infections or non-HIV-related devel-
opmental, neurologic, psychiatric, or metabolic conditions
that might affect CNS functioning (e.g., loss of conscious-
ness exceeding 30 min, psychosis, substance dependence).
The diagnosis of HIV encephalitis was based on the pres-
ence of microglial nodules, astrogliosis, HIV p24-positive
cells, and myelin pallor.
Determination of HIV p24 levels in postmortem samples
HIV-1 p24 levels in postmortem tissues were determined
using a commercially available p24 enzyme-linked immu-
nosorbent assay (ELISA; NEK050001KT, PerkinElmer,
Waltham, MA, USA). In brief, as previously described
(Hashimoto et al. 2002), tissues from human brain samples
(0.1 g) were homogenized in 0.7 mL of fractionation buffer
containing phosphatase and protease inhibitor cocktails
(Calbiochem, San Diego, CA, USA). Samples were pre-
cleared by centrifugation at 5,000×g for 5 min at room
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temperature. Homogenate was analyzed for protein quantity
by BCA assay (Thermo Scientific) and then 100 μg of
protein from each sample was assayed for p24 using the
manufacturer’s protocol.
Generation of gp120 tg mice
For studies of autophagy function, an animal model of HIV
protein-mediated neurotoxicity, aged (12 months) tg mice
expressing high levels of gp120 under the control of the
glial fibrillary acidic protein (GFAP) promoter were used
(Toggas et al. 1994). These mice develop neurodegeneration
accompanied by astrogliosis, microgliosis, and memory def-
icits in the water maze test (Toggas et al. 1994). The mice
were sacrificed within 1 week of behavioral testing and
brains were removed for biochemical analyses of frozen or
fixed brain tissues.
Construction of lentivirus vectors
The mouse beclin-1 cDNA (Open Biosystems) was PCR
amplified and cloned into the third-generation self-
inactivating lentivirus vector (Naldini et al. 1996a, b) with
the CMV promoter driving expression producing the vector
LV-beclin-1. Lentiviruses expressing beclin-1, luciferase or
empty vector (as controls) was prepared by transient trans-
fection in 293 T cells (Naldini et al. 1996a, b; Tiscornia et al.
2006; Spencer et al. 2009).
Mouse lines and intracerebral injections of lentiviral vectors
A cohort of aged (12 months) mice (n020), gp120 tg (n0
10), and control mice (n010) were injected with 3 μl of the
lentiviral preparations (2.5×107 TU) into the temporal cor-
tex (using a 5 μl Hamilton syringe). Briefly, as previously
described (Marr et al. 2003), mice were placed under anes-
thesia on a Koft stereotaxic apparatus and coordinates (hip-
pocampus: AP, 2.0 mm; lateral, 1.5 mm; depth, 1.3 mm and
cortex: AP, 0.5 mm; lateral, 1.5 mm; depth, 1.0 mm) were
determined as per the Franklin and Paxinos (1997) atlas.
The lentiviral vectors were delivered using a Hamilton sy-
ringe connected to a hydraulic system to inject the solution
at a rate of 1 μl every 2 min. To allow diffusion of the
solution into the brain tissue, the needle was left for an
additional 5 min after the completion of the injection.
Mice received unilateral injections (right side) to allow
comparisons against the contralateral side, with either LV-
beclin-1 (n05) or LV-control (n05). Additional controls
were performed by injecting non-tg littermates with either
LV-beclin-1 (n05) or LV-control (n05). Mice survived for
3 months after the lentiviral injection. As an additional
control for LV injection, age-matched littermates were
injected with LV-luciferase.
Since no differences were observed between the LV-
control and the LV-luciferase, all data presented in this paper
are shown with the LV-control vector. Following National
Institutes of Health (NIH) guidelines for the humane treat-
ment of animals, mice were anesthetized with chloral hy-
drate and flush-perfused transcardially with 0.9 % saline.
Brains and peripheral tissues were removed and divided in
sagittal sections. The right hemibrain was post-fixed in
phosphate-buffered 4 % PFA (pH7.4) at 4 °C for 48 h for
neuropathological analysis, while the left hemibrain was
snap-frozen and stored at −70 °C for subsequent RNA and
protein analysis.
Antibodies
For western blot and immunohistochemical analysis of the
autophagy pathway, polyclonal antibodies against GFAP
(MAB3402, dilution 1:500, Millipore), cathepsin-D
(1:500, Calbiochem, San Diego, CA, USA), Iba-1
(1:1,000, Wako Corp., Japan), microtubule-associated pro-
tein (MAP) 2 (MAP378, 1:250, Millipore), LC3 (1:1,000,
Abcam), mTor (1:1,000, Sigma), beclin-1 (1:1,000, Novus
Biologicals, Littleton, CO, USA).
Immunoblot analysis
Frontal cortex tissues from human and mouse brains were
homogenized and fractionated using a buffer that facilitates
separation of the membrane and cytosolic fractions
(1.0 mmol/L HEPES, 5.0 mmol/L benzamidine, 2.0 mmol/
L 2-mercaptoethanol, 3.0 mmol/L EDTA, 0.5 mmol/L mag-
nesium sulfate, 0.05 % sodium azide; final pH, 8.8). In brief,
as previously described (Hashimoto et al. 2002), tissues
from human and mouse brain samples (0.1 g) were homog-
enized in 0.7 mL of fractionation buffer containing
Table 1 Summary of subject demographic and brain pathology information
Group n Gender F/M Age PMI (h) Brain weight (g) Brain pathology
Under 50 (young) 50 5/45 39.2±6.04 14.0±12.13 1317±131.3 20 Normal, 1 Alzheimer type II gliosis, 6 microglial
nodule encephalitis, 17 HIV encephalitis, 6 other
50 and older (aged) 33 5/28 55.2±5.51 23.6±24.49 1336±176.5 13 Normal, 6 Alzheimer type II gliosis, 1 microglial
nodule encephalitis, 8 HIV encephalitis, 5 other
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phosphatase and protease inhibitor cocktails (Calbiochem,
San Diego, CA, USA). Samples were precleared by centri-
fugation at 5,000×g for 5 min at room temperature.
Supernatants were retained and placed into appropriate ul-
tracentrifuge tubes and were centrifuged at 436,000×g for
1 h at 4 °C in a TL-100 rotor (Beckman Coulter, Brea, CA,
USA). This supernatant was collected as representing the
cytosolic fraction, and the pellets were resuspended in
0.2 mL of buffer and rehomogenized for the membrane
fraction.
After determination of the protein content of all samples
by BCA protein assay (Thermo Fisher Scientific, Rockford,
IL, USA), homogenates were loaded (20 μg total protein/
lane), separated on 4–12 % Bis-Tris gels and electrophor-
esed in 5 % HEPES running buffer, and blotted onto
Immobilon-P 0.45 μm membrane using NuPage transfer
buffer. The membranes were blocked in either 5 % nonfat
milk/1 % BSA in phosphate-buffered saline (PBS)+0.05 %
Tween-20 (PBST) or in 5 % BSA in PBST for 1 h.
Membranes were incubated overnight at 4 °C with primary
antibodies. Following visualization, blots were stripped and
probed with a mouse monoclonal antibody against Actin
(1:2,000, mab1501, Millipore, Billerica, MA, USA) as a
loading control. All blots were then washed in PBS,
0.05 % tween-20 and then incubated with secondary
species-specific antibodies (American Qualex, 1:5,000 in
BSA-PBST) and visualized with enhanced chemilumines-
cence reagent (Perkin-Elmer). Images were obtained and
semiquantitative analysis was performed with the
VersaDoc gel imaging system and Quantity One software
(Bio-Rad).
immunohistochemistry, image analysis, and laser scanning
confocal microscopy
Briefly, as previously described (Masliah et al. 2003), free-
floating 40 μm thick vibratome sections were washed with
Tris-buffered saline (TBS, pH7.4), pretreated in 3 % H2O2,
and blocked with 10 % serum (Vector Laboratories,
Burlingame, CA, USA), 3 % bovine serum albumin
(Sigma), and 0.2 % gelatin in TBS-Tween. For human
brains, sections from the midfronal cortex were used; for
the mice, sagittal sections from the complete brain were
studied. Sections were incubated at 4 °C overnight with
the primary antibodies. Sections were then incubated in
secondary antibody (1:75, Vector), followed by Avidin D-
horseradish peroxidase (HRP, ABC Elite, Vector) and
reacted with diaminobenzidine (0.2 mg/ml) in 50 mM Tris
(pH7.4) with 0.001 % H2O2. Control experiments consisted
of incubation with pre-immune rabbit serum. To investigate
the effects of postmortem delay and fixation on the levels of
mTor immunoreactivity, preliminary studies were performed
in a subset of cases (n05) with postmortem delay ranging
from 4 to 48 h. In addition, double immunolabeling studies
were performed as previously described (Spencer et al.
2009) to determine the cellular localization of the autophagy
markers. For this purpose, vibratome sections from the
young and aged HIV+ and HIVE+ cases as well as of the
non-tg and gp120 tg mice were immunostained with anti-
bodies against the neuronal marker MAP2 (mouse mono-
clonal) and antibodies against either LC3, mTor, or
Cathepsin-D (rabbit polyclonal). Sections were then reacted
with secondary antibodies tagged with FITC to detect
MAP2 and mTor and with the tyramide Red amplification
system (Perkin-Elmer) to detect Cathepsin-D. Conversely
for the experiments analyzing LC3, this autophagy marker
was detected with FITC while MAP2 was detected with the
tyramide Red amplification system (Perkin-Elmer). Sections
were mounted on superfrost slides (Fisher) and coverslipped
with media containing DAPI. Double-immunolabeled sec-
tions were imaged with the laser scanning confocal micro-
scope as described below.
Immunostained sections were imaged with a digital
Olympus microscope and assessment of levels of GFAP,
Iba1, beclin-1, Cathepsin-D, and mTor immunoreactivity
was performed utilizing the Image-Pro Plus program
(Media Cybernetics, Silver Spring, MD, USA). For each
case, a total of three sections (10 images per section) were
analyzed in order to estimate the average number of immu-
nolabeled cells per unit area (square millimeter) and the
average intensity of the immunostaining (corrected optical
density).
For confocal images (LC3 and MAP2), all sections were
processed simultaneously under the same conditions and
experiments were performed twice for reproducibility.
Sections were imaged with a Zeiss 63× (N.A. 1.4) objective
on an Axiovert 35 microscope (Zeiss, Germany) with an
attached MRC1024 laser scanning confocal microscope
system (BioRad, Hercules, CA, USA).
Analysis of neurodegeneration
Neuronal structural integrity was evaluated as previously
described (Rockenstein et al. 2005a, b). In brief, blind-
coded, 40 μm thick microtome sections from human and
mouse brains fixed in 4 % paraformaldehyde were immu-
nolabeled with mouse monoclonal antibodies against MAP2
(1:200). After overnight incubation, sections were incubated
with fluorescein isothiocyanate-conjugated secondary anti-
bodies (1:75; Vector Laboratories, Burlingame, CA, USA),
transferred to SuperFrost slides (Fisher Scientific, Tustin,
CA, USA), and mounted under glass coverslips with anti-
fading medium (Vector Laboratories). All sections were
processed under the same standardized conditions. The
immunolabeled blind-coded sections were serially imaged
with a laser scanning confocal microscope (MRC-1024;
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Bio-Rad) and analyzed with ImageJ v1.43 software (NIH,
Bethesda, MD, USA), as previously described (Crews et al.
2010). For each mouse, a total of three sections were ana-
lyzed; for each section, four fields in the frontal cortex and
hippocampus were examined. Results were expressed as
percent area of the neuropil occupied by immunoreactive
signal. All sections were processed under the same stan-
dardized conditions. Immunostained sections were imaged
with a digital Olympus microscope and the Image-Pro Plus
program (version 4.5.1, Media Cybernetics).
Statistical analysis
All the analyses were conducted on blind-coded samples.
After the results were obtained, the code was broken and
data were analyzed with the StatView program (SAS
Institute, Inc., Cary, NC, USA). Comparisons among groups
were performed with one-way ANOVA, unpaired Student’s
t test and Chi-square analysis. All results were expressed as
mean±SEM. The differences were considered to be signif-
icant if p values were <0.05.
Role of the funding source
The funding source had no role in the study design, data
collection, data analysis, data interpretation or writing of
this report. The corresponding author had full access to all
the data and had final responsibility for the decision to
submit the paper for publication.
Results
Clinical and neuropathological characteristics of young
and aged donors with and without HIVE
Before analyzing autophagy protein levels, we first meticu-
lously collected and characterized clinical and neuropatho-
logical aspects of the young and aged HIV+ cohort. For this
purpose, at first, a total of 83 autopsy cases were analyzed
(n050 young and n033 aged). In order to assess relevant
differences between postmortem brain samples from young
and aged HIV patients, we characterized the cohorts by
brain pathology, CD4+ cell count, viral load, and neuropsy-
chological impairment status. Table 1 demonstrates both
young and aged cohorts were predominantly male and
40 % of each cohort had normal brain pathology (Table 1).
Only one (2 %) of the young cases showed Alzheimer type
II gliosis, whereas six (18 %) of the 33 aged patients showed
Alzheimer type II gliosis (Table 1). Conversely, one (3 %) of
the aged patients presented microglial nodule encephalitis,
while microglial nodule encephalitis was present in six
(12 %) of the young patients (Table 1). Seventeen (33 %)
of young cases showed HIVE versus eight (24 %) among
the aged patients (Table 1). Of the 83 autopsy cases, com-
plete neurovirological and neurological analysis was avail-
able in 55 cases (n031 younger and n024 aged). Further
analyses revealed that young cases had significantly
(p<0.05) lower CD4+ cell counts compared to aged
patients, and significantly (p<0.05) higher plasma VL
(Table 2). CSF VL was equivalent between young and aged
groups (Table 2). Assessment of neuropsychological impair-
ment showed that nine (18 %) of the young group suffered
HAD, and another nine (18 %) suffered minor cognitive
motor deficits, whereas only one (3 %) and two (6 %)
donors of the aged group suffered from these afflictions,
respectively (Table 2). Twenty percent of cases from each
group presented NPI-other (O), and the aged group had two
NPI-unknown (U) cases (Table 2). Five of the young
patients were unable to complete assessment and two were
normal, while four of the aged patients were unable to
complete assessment and six were normal (Table 2). These
data indicate stark differences in the pathology and neuro-
psychological state between young and aged cases in this
HIV+ cohort.
HIV capsid protein, p24, levels are increased in aged
and neuropsychological impaired patients
To further characterize neuropathology among the young
and aged cohorts, p24 levels in postmortem brain tissue
from young and aged HIV patients were measured by
ELISA and correlated to neuropathology and neuropsycho-
logical impairment. p24 levels were statistically equal be-
tween young and aged HIV patients (Fig. 1a). For this
analysis, tissues were available for all 83 cases, of them
n050 young (n033 HIV+ and n017 HIVE) and n033 aged
(n023 HIV+ and n010 HIVE). p24 levels were increased in
postmortem tissues from young and aged HIVE patients
compared to age-matched HIV controls (Fig. 1b, p<0.05
and p<0.001, respectively). p24 levels in postmortem tis-
sues from aged HIVE patients were significantly increased
compared to young HIVE patients (Fig. 1b, p<0.001).
Similarly, p24 levels are increased in young and aged
patients with any neuropsychological impairment compared
to age-matched HIV controls (Fig. 1c). p24 levels were
highest in the aged patients with neuropsychological impair-
ment (Fig. 1c). Data represent analysis of the entire cohort
of HIV+ and HIVE donor brains.
Neuroinflammation and neuropathology were increased
in postmortem brains from aged HIVE patients
Next, we measured levels of inflammatory and neuronal
markers by immunohistochemical analysis in a subgroup
of n029 postmortem cases, n015 young (n07 HIV+ and
J. Neurovirol. (2013) 19:89–101 93
n08 HIVE) and n014 aged (n08 HIV+ and n06 HIVE).
Vibratome sections from paraformaldehyde fixed frontal
cortex were used. Inflammatory markers GFAP and Iba-1
were increased, while MAP2 (somato-dendritic marker)
immunostaining was decreased in brain tissue from aged
HIVE patients compared to young HIVE patients (Fig. 2a–
c). Astroglial marker, GFAP immunoreativity, and signal
were elevated in young and aged HIVE tissues versus young
and aged HIV+ samples; however, GFAP signal was most
intense in tissues from aged HIVE patients (Fig. 2a). The
microglial marker, Iba-1, signal intensity was increased in
brain tissues of young and aged HIVE patients compared to
HIV+ patients from both groups, with cells from HIVE
tissues having more extended processes in greater numbers
(Fig. 2b). MAP2 neuronal marker immunoreactivity was
opposite that of GFAP and Iba-1 staining; young and aged
HIVE tissues had reduced MAP2 signal compared to young
and aged HIVE tissues (Fig. 2c). Furthermore, MAP2 stain-
ing in aged HIVE tissues was the most punctate and discon-
tinuous, as indicated by the white arrows (Fig. 2c). GFAP
and Iba-1 optical density in HIVE samples was significantly
(p<0.001) increased compared to age-matched HIV+ sam-
ples (Fig. 2d–e). GFAP optical density was significantly (p<
0.05) increased in aged HIVE samples compared to young
HIVE samples (Fig. 2d). Quantification of MAP2 neuronal
marker indicated area of the neuropil stained decreased from
26 % (in young HIV+ patients) to 20 % (area of neuropil in
young HIVE patients; p<0.01). MAP2 levels were de-
creased from 24 % (area of the neuropil in aged HIV+
patients) to 16 % (area of neuropil in aged HIVE patients;
Fig. 2e, p<0.001). MAP2 (16 % of the neuropil) levels in
aged HIVE samples were significantly (p<0.05) reduced
compared to young HIVE samples (21 % of neuropil).
Autophagy markers are reduced in aged HIVE patients
compared to young HIVE patients
To analyze autophagy pathway activity, aged and young
HIV+ and HIVE brain beclin-1, cathepsin-D, LC3, and
mTor were analyzed immunohistochemistry (Fig. 3a–h).
Immunohistochemical analysis of pyramidal neurons in
layers II–III and V of the midfrontal cortex from young
and aged HIV+ and HIVE patients showed beclin-1,
cathepsin-D, and LC-3 levels were increased in young
HIVE versus young HIV+ samples; however, levels of all
three autophagy markers were decreased in aged HIVE
versus aged HIV+ brains (Fig. 3a–c). For each case analysis
of beclin-1, cathepsin-D and LC-3 immunoreactivity was
performed in comparable layers of the neocortex to assure
consistent comparisons. The black box inset denotes area of
high cathepsin-D immunoreactivity in young HIV+ patients
(Fig. 3b). White arrows indicate LC3 staining of autopha-
gosomes in neurons (Fig. 3c). Levels of mTor were moder-
ate in young HIV+ and HIVE brains, but were increased in
Table 2 CD4+ cell count, plasma VL, presence of neuropsychological impairment, and CSF VL in the young and aged HIV+ cohort
Group CD4* Log plasma VL* Log CSF VL NPI ARV+/−
Under 50 (young) 70.2±151.9 (n029) 4.53±1.39 (n029) 3.14±1.35 (n030) 9 HAD, 9 MCMD, 3 NPI, 10 NPI-O,
5 unable, 2 normal
16/15
50 and older (aged) 241.2±325.4 (n025) 3.64±1.70 (n023) 2.64±1.25 (n021) 1 HAD, 2 MCMD, 3 NPI, 7 NPI-O,
2 NPI-U, 4 unable, 6 normal
14/10
n number of independent donors, MCMD minor cognitive motor deficits
*p<0.05
Fig. 1 p24 levels in postmortem samples from young and aged HIVE
patients and in patients with neuropsychological impairment. a p24
protein levels measured by ELISA from postmortem brain samples
from young and aged HIV+ patients. b p24 protein levels in postmor-
tem samples from young and aged cases categorized by HIV+ and
HIVE. c Compares young and aged HIV+ patients further categorized
as no psychological impairment (NPI) or presence of any psycholog-
ical impairment (PI). Statistical significance (*p<0.05, ***p<0.001,
one-way ANOVA, post hoc Fisher’s test) compared to HIV+. These
data represent compilations of the entire cohort of HIV+ and HIVE
donor brains (total n083), of them n050 young (n033 HIV+ and n017
HIVE) and n033 aged (n023 HIV+ and n010 HIVE)
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aged HIV+ and HIVE brains (Fig. 3d). Beclin-1 optical
density is significantly (p<0.001) increased in young
HIVE compared to young HIV+ samples; however, beclin-
1 optical density in aged HIVE samples is significantly (p<
0.001) reduced compared to levels in young HIVE samples
(Fig. 3e). Cathepsin-D optical density levels were signifi-
cantly increased in young HIVE compared to levels in
young HIV+ brains and similar to beclin-1 levels,
cathepsin-D levels in aged brains were significantly (p<
0.01) reduced compared to young HIVE samples (Fig. 3f).
Quantification of LC3 confocal image pixel intensity
revealed LC3 levels in young HIVE brains are significantly
(p<0.001) reduced compared to levels young HIV+ brains
(Fig. 3g). Aged HIV+ and HIVE brain LC3 levels are
equivalent but significantly (p<0.001) reduced compared
to young HIVE brain LC3 levels. Quantification of mTor
optical density reveals young HIV+ and HIVE brains have
similar mTor expression; however, mTor levels in aged HIV+
and HIVE were increased compared to young samples
(Fig. 3h). Furthermore, mTor levels in aged HIVE samples
were significantly (p<0.01) higher than levels in aged HIV+
samples (Fig. 3h). To confirm that the alterations in markers of
autophagy were in pyramidal neurons of layers II–III and V,
double labeling and confocal microscopy studies were per-
formed. Both in the young and aged HIV+ cases, most (ap-
proximately 90 %) of the cathepsin-D, LC3, and mTor
immunoreactive granules in the cytoplasm of cells were ob-
served in MAP2 immunoreactive neurons (Fig. 4a).
To corroborate immunohistochemical data beclin-1, LC3,
mTor, and actin were measured by immunoblot in postmortem
brain samples from aged and young HIV+ and HIVE patients
(Fig. 5a–c). Beclin-1 and LC3 signals were increased in young
HIVE compared to young HIV+ samples; however, beclin-1
and LC3 signals were decreased in aged HIVE compared to
aged HIV+ samples (Fig. 5a). Analysis of band density
revealed that young HIVE beclin-1 levels were increased
2.5-fold compared to young HIV+ samples (p<0.05); howev-
er, aged HIVE sample beclin-1 levels were decreased by 60%
compared to aged HIV+ samples (Fig. 5b, p<0.05). Similarly,
LC3 band density analysis revealed that levels were increased
in young HIVE compared to young HIV+ patients (p<0.05),
yet aged HIVE LC3 levels were significantly reduced
(p<0.05) compared to aged HIV+ LC3 levels (Fig. 5c).
Autophagy markers are reduced in aged gp120-tg mice;
lentivirus delivery of beclin-1 restores autophagy marker
expression
To investigate alterations in the autophagy pathway in an
experimental model of HIV protein neurotoxicity, immuno-
chemical analysis was performed in aged (12 months)
gp120 tg and non-tg mice. Immunohistochemical analysis
showed that compared to aged non-tg mice, levels of beclin-
1, cathepsin-D, and LC3 are reduced and mTor is increased
in brains of aged gp120 tg mice. Lentiviral-mediated deliv-
ery of beclin-1 via stereotaxic injection to the temporal
cortex of gp120 tg mice increased beclin-1, cathepsin-D,
and LC3 levels in aged non-tg and aged gp120 tg mice
(Fig. 6a–c). Beclin-1 delivery significantly (p<0.05) reduced
mTor levels in aged gp120 tg mice (Fig. 6d). Quantification of
Fig. 2 Immunohistochemical localization of GFAP, Iba1, and MAP2
in postmortem brain samples from young and aged HIV+ and HIVE
patients. a–c GFAP, Iba1, and MAP2 signal localization in young aged
HIVE patients. d GFAP optical density in brains from young and aged
HIV+ and HIVE patients. e Iba-1 optical density in brains from young
and aged HIV+ and HIVE patients. f MAP2 signal as percent of the
neuropil stained. Arrows indicate fragmented MAP2 staining and trun-
cated axons/soma. A total of n029 postmortem cases were analyzed, of
them n015 young (n07 HIV+ and n08 HIVE) and n014 aged (n0
8 HIV+ and n06 HIVE)
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autophagy marker optical density or pixel intensity showed
beclin-1, cathepsin-D, and LC3 levels were significantly
(p<0.05) reduced in aged gp120 tg brains compared to levels
in aged non-tg control mice brains (Fig. 6e–g). Levels of mTor
immunoreactivity were increased in aged gp120 tg mice com-
pared to aged non-tg mice, and this was reversed by LV-
mediated beclin-1 delivery (Fig. 6h). To confirm that the
effects of the lentivirus on markers of autophagy are
in pyramidal neurons, double labeling and confocal mi-
croscopy studies were performed. Both in the non-tg
and gp120 tg mice treated with the LV-beclin1 the
majority (approximately 90 %) of the cathepsin-D,
LC3, and mTor immunoreactive cells were localized to
MAP2 immunostained cells (Fig. 4a).
Fig. 3 Immunohistochemical comparisons of autophagy markers in
young vs aged HIV+ and HIVE patients. Postmortem brain samples
were immunostained for beclin-1, cathepsin-D, LC3, and mTor and
analyzed with confocal or bright-field microscopy. a–d Beclin-1,
cathepsin-D, LC3, and mTor immunoreactivity in young and aged
HIV+ and HIVE brain tissues. The black box inset (b) denotes area
of high Cathepsin-D immunoreactivity in young HIV+ patients. White
arrows in c indicate LC3-positive autophagosome localization. Semi-
quantitative analysis of e beclin-1, f cathepsin-D, g LC3, and h mTor
immunoreactivity. Statistical significance (*p<0.05, one-way
ANOVA, post hoc Fisher’s test) compared to HIV+. A total of n029
postmortem cases were analyzed, of them n015 young (n07 HIV+ and
n08 HIVE) and n014 aged (n08 HIV+ and n06 HIVE)
Fig. 4 Double immunolabeling studies for autophagy and neuronal
markers in HIV+ and gp120 tg mice. a Representative images obtained
with the laser confocal microscopy. MAP2 immunolabeled neurons in
layer V of the frontal cortex from an aged patient with HIV+ showing
the colocalization of Cathepsin D, LC3, and mTor with the neuronal
marker. Arrows point to the granular structures in the cytoplasm of
neurons representing lysosomes and autophagolysosomes. Bar 10 μm.
b Representative laser confocal microscopy images from an aged
gp120 tg mouse treated with LV-beclin-1. MAP2 immunolabeled neu-
rons in layer V of the frontal cortex co-localized with cathepsin D,
LC3, and mTor. Arrows granular structures in the cytoplasm of neurons
representing lysosomes and autophagolysosomes. Bar 10 μm
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LV-mediated beclin-1 delivery reduces neuroinflammation
and neurodegeneration in aged gp120 tg mice brains
Overexpression of beclin-1 from the lentivirus reduced
astrogliosis and microgliosis markers and neurodegenera-
tion in gp120 tg mice. Immunohistochemical analyses of
gp120 tg mice brains show GFAP and Iba1 staining was
increased while MAP2 staining was decreased compared to
control non-tg mice (Fig. 7a–c). GFAP positive cells were
more numerous with extended processes and displayed
more intense GFAP signal (Fig. 7a). Similarly, Iba1 signal
was increased in gp120 tg mouse brains compared to non-tg
control mice (Fig. 7b). gp120 tg mouse brains expressed
reduced levels of MAP2 in a more punctate and discontin-
uous pattern (Fig. 7c). Compared with the LV-control, LV-
beclin-1 injection reduced GFAP and Iba1 signal increased
Fig. 5 Immunoblot comparisons of autophagy markers in brains of
young vs aged HIV+ and HIVE postmortem tissues. a Immunoblot
image of a representative subset of samples labeled for beclin-1, LC3
mTorb and Actin. b–d Beclin-1, LC3, and mTor band intensity nor-
malized to actin expression, respectively, from young and aged HIV+
and HIVE patients. For statistics, a total of n029 postmortem cases
were analyzed, of them n015 young (n07 HIV+ and n08 HIVE) and
n014 aged (n08 HIV+ and n06 HIVE). Statistical significance (*p<
0.05, one-way ANOVA, post hoc Fisher’s test) compared to HIV+
Fig. 6 Lentivirus-mediated delivery of beclin-1 to aged gp120 tg mice
increases autophagy markers. Immunohistochemical and confocal
analysis 3 months after injection. a Beclin-1 immunoreactivity in
non-tg and gp120 tg mice that were injected with LV-control and LV-
beclin-1. b Cathepsin-D immunoreactivity in non-tg and gp120 tg mice
that were injected with LV-control and LV-beclin-1. c LC3 immunore-
activity in non-tg and gp120 tg mice that were injected with LV-control
and LV-beclin-1. d mTor immunoreactivity in non-tg and gp120 tg
mice that were injected with LV-control and LV-beclin-1. Semiquanti-
tative levels of e beclin-1, f cathepsin-D, g LC3, and h mTor illustrated
as optical density (e, f, and h) or pixel intensity (g). Samples were
further stained with DAPI to visualize nuclei (blue). Statistical signif-
icance (*p<0.05, one-way ANOVA, post hoc Fisher’s test) compared
to non-tg controls. All panels are from the frontoparietal cortex of 12-
month-old mice, a total of n020 mice (n05 per group) were included
for the study
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and normalized MAP2 staining in gp120 tg mouse brains
(Fig. 7a–c). Quantification of GFAP, Iba1, and MAP2 im-
munoreactivity corroborated evidence that LV-beclin-1 re-
duced astrogliosis, microgliosis, and neurodegeneration in
GFAP gp120 tg mice (Fig. 7d–f). GFAP optical density was
equivalent between LV-control and LV-beclin-1 treated non-
tg mice; however, GFAP optical density was significantly
(p<0.05, twofold) elevated in gp120 tg mice brains com-
pared to non-tg mice (Fig. 7d). LV-beclin-1 significantly
(p<0.05, −30 %) reduced GFAP optical density in gp120
tg mice brains (Fig. 7d). Iba1 staining was significantly
(p<0.05) elevated in gp120 tg mice compared to non-tg
mice; however, LV-beclin-1 significantly (p<0.05) reduced
Iba1 staining in fp120 tg mouse brains (Fig. 7e). The area of
the neuropil stained by MAP2 was significantly (p<0.05,
−25 %) reduced in gp120 tg mouse brains compared to non-
tg mice; LV-beclin-1 restored gp120 tg brain MAP2 staining
to levels of non-tg mice (Fig. 7f).
Discussion
In the current study, we show for the first time differential
levels of autophagy proteins in postmortem brain tissue
samples from aged HIVE and young HIVE patients. While
the young HIVE group display increased autophagy
markers, the aged HIVE group showed reduced autophagy
pathway proteins. Viral protein and inflammatory marker
levels were increased while autophagy proteins beclin-1,
LC3 and the neuronal marker MAP2 were reduced in
HIVE brain tissues from aged donors compared to those
from young donors. Similarly, analysis of aged gp120 tg
mouse brains showed reduced autophagy marker expression
and increased neurodegeneration compared to aged non-tg
mice. LV-beclin-1 gene transfer restored autophagy markers
and reduced neuroinflammation and neurodegeneration in
aged gp120 tg mouse brains. Previous studies have shown
that HIV can alter the autophagy pathway, but these studies
show possible reduced autophagy function in aged HIVE
patients and increased inflammation markers accompanied
with simplified neuronal synaptic complexity compared to
young HIVE donors. Furthermore, LV-mediated beclin-1
gene transfer restores autophagy function and reduces neu-
rodegeneration in aged gp120 tg mice. HIV infection in
young patients may differ markedly to that in aged patients
with respect to autophagy and neuronal injury; these data
corroborate evidence that HIV infection may exacerbate
consequences of normal aging and may provide a potential
therapy for aged HAND patients.
The present studies are consistent with recent findings
that suggest the autophagy pathway is dysregulated during
AD, PD, and HIV (Ebrahimi-Fakhari et al. 2011; Pickford et
al. 2008; Zhou et al. 2011); however, this is the first report
of distinct differences in autophagy marker expression
among young and aged HIVE patients. A survey of HIV
patients showed overall autophagy markers are increased in
postmortem samples from HIV-infected individuals (Zhou
et al. 2011). By further categorizing patients according to
Fig. 7 Lentivirus-mediated delivery of beclin-1 to aged gp120 tg mice
ameliorates neurodegenerative pathology. Non-tg and gp120 mice
were injected with LV-control or LV-beclin-1 and after 3 months of
the injection, mice were immunostained and analyzed with confocal
microscopy or bright-field microscopy. a–c Effects of LV-beclin-1 on
patterns of a GFAP, b Iba1, and c MAP2 immunoreactivity. d
Semiquantitative analysis of GFAP optical density. e Number of Iba-
1+ cells. f MAP2 immunoreactivity illustrated as percent area of the
neuropil. Statistical significance (*p<0.05, one-way ANOVA, post hoc
Fisher’s test) compared to non-tg controls. All panels are from the
frontoparietal cortex of 12-month-old mice, a total of n020 mice (n05
per group) were included for the study
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age and HIVE status, the current studies revealed distinct
differences in aged and young HIVE brains. These differ-
ences in autophagy function among young and aged HIVE
patients may contribute to the growing list of chronic
comorbidities among aged HIV patients. The differences
observed in brains from deceased young versus aged
HIVE patients suggest that two distinct types of infection
may be responsible for the differences observed between
young and aged HIVE patients: (1) viremia is robust and
infiltrates the CNS leading to early neural complications and
death (young) or (2) viremia is subdued throughout infec-
tion, the CNS is not dramatically affected early on, yet long-
term infection gradually increases neuroinflammation and
neurodegeneration (aged). HIV patients that live over
50 years may harbor a low but chronic viral burden that
can limit normal autophagy function and lead to proteino-
pathies such as seen in AD and PD. Another alternative is
that HIV infection progresses similarly in most patients but
some patients escape the battery of opportunistic infections
to live a longer life. The compensatory autophagy response
seen in young patients may be meant to clear excessive toxic
molecule build up until the system is overwhelmed and the
molecular recycling system fails. Reduced autophagy
marker levels detected in aged HIVE samples may repre-
sent less viable cells with reduced capacity to perform
normal physiological processes, such as autophagy.
Consistent with this notion, Aβ expression correlates with
age in postmortem samples from HIVE patients, and in
the second scenario this may be a natural occurrence of
most chronic HIV infections (Achim et al. 2009; Khanlou
et al. 2009). In either case, understanding how HIV affects
neuronal autophagy may lead to therapies that slow down
neurodegeneration. Importantly, neither of these scenarios
considers those individuals who contract HIV infection
after turning 50, for which alternative patterns of disease
have been reported (Erlandson et al. 2012). Additional
studies using samples from large cohorts of HIV patients
combined with animal models and cellular-based studies
will prove valuable in dissecting the complications of
aging with neuroAIDS.
Beclin-1 and LC3 are essential proteins in the autophagy
pathway, and interference at either level may result in cel-
lular toxicity (Kragh et al. 2012). Beclin-1 mediates auto-
phagosome nucleation and LC3 is an integral autophagy
protein that facilitates autophagosome elongation and clo-
sure and may also be involved in disease (Dinkins et al.
2010; Gannage et al. 2010; Kyei et al. 2009). Despite
increased autophagy machinery, HIV patients have in-
creased Aβ and α-synuclein accumulation in the brain
(Achim et al. 2009; Khanlou et al. 2009). These and other
reports suggest that dysfunctional autophagy is associated
with neurodegenerative diseases and may exacerbate prob-
lems associated with HIV infection of the CNS. In this
context, it may be possible to reintroduce functional autoph-
agy by gene transfer to ameliorate HIVE phenotypes.
It was recently reported that HIV-1 infection inhibits
autophagy pathways in monocytes, but no direct effect on
neurons has been shown (Van Grol et al. 2010). Kyei et al.
showed that the HIV-1 protein Nef interacts with autophagy
pathways in macrophages (Kyei et al. 2009). In subsequent
findings, groups have shown that HIV-1 may highjack the
autophagy pathway to promote replication (Gregoire et al.
2011; Killian 2012). Despite these advances, it is not known
if HIV directly or indirectly affects neuronal autophagy and
ultimately contributes to neurodegeneration. Our current
studies show aged HIVE patients express increased neuro-
inflammatory markers and reduced neuronal markers, indi-
cating progressed neurodegeneration, and loss of synaptic
processes may be associated with decreased autophagy-
related proteins (beclin-1 and LC3). The gp120 tg mouse
serves as a model for HIV-1-protein mediated neurotoxicity
and the mice present neuropathology and behavioral deficits
similar to those seen in HAND patients (Toggas et al. 1994).
Furthermore, in the α-syn tg mouse model for PD, LV-
mediated delivery of beclin-1 to the CNS reversed neuropa-
thology and reduced the accumulation of α-syn (Spencer et
al. 2009). The current studies further support the hypothesis
that proteinopathies may be due to dysfunctional autophagy
and that normal molecular recycling may be restored via LV-
mediated beclin-1 gene transfer. Indeed, LV-beclin-1 ame-
liorated astrogliosis, microgliosis, and neurodegeneration in
the gp120 tg mouse model and may serve as a therapy for
aged HAND patients.
Impetus has been placed on understanding how aging
may exacerbate HAND. Healthy individuals >65 are desig-
nated elderly by the Centers for Disease Control, but HIV
infected individuals are designated “aged” HIV patients at
>50, due to progressed signs of aging. It is predicted that by
2015, over 50 % of AIDS cases in the USA, and 15 % of
newly diagnosed cases will be >50 (Erlandson et al. 2012;
Watkins and Treisman 2012). Reports have demonstrated
that aged HIV patients have increased risk of severe depres-
sion and cognitive impairment, less time between infection
and AIDS diagnosis and reduced T-lymphocyte proliferation
(Watkins and Treisman 2012). Further studies are needed to
characterize and combat HIV in this particularly vulnerable
group. Our data support the hypothesis that HIVexacerbates
the effects of aging and implicate dysregulated autophagy as
a possible cause of HAND.
Studies on mechanisms of HIV pathogenesis in aged
patients are lacking; aging with HIV is a relatively novel
problem. Most studies consider neuroAIDS with respect to
the HIV-infected population as a whole, yet physicians and
the CDC note stark differences in the progression of disease
between young and aged groups (Erlandson et al. 2012;
Watkins and Treisman 2012). In an effort to understand
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differences in HIV pathogenesis between young and aged
patients, we surveyed 83 HIV patients, 33 of which were
>50 years old. Among the young and aged groups, 40 % of
each group was classified as normal brain pathology; howev-
er, 18 % of the aged group presented with Alzheimer type II
gliosis in contrast to only one patient from the young group.
Also noteworthy, 34 % of the young group had encephalitis
versus 24% of the aged group. High VL and encephalitis may
have contributed to the premature demise of young patients,
whereas persistent low-level infection, as seen in aged
patients, may contribute to the Alzheimer-like pathology. In
contrast to past reports, the current studies indicate that CD4+
cell count was higher in aged brains, and CNS plasma viral
burden is reduced in aged HIV patients; yet, p24 and inflam-
matory markers are increased compared to their younger
counterparts. Chronic inflammation may promote long-term
deleterious changes in gene expression in aged HIV infected
individuals, which may explain how aged HIV patients
suffer increased morbidity despite higher CD4+ cell
counts. Cohort size and population dynamics all contribute
to data variability.
The proportion of HIV-1-infected individuals over the
age of 50 is rapidly increasing, yet therapies to prevent or
treat HAND remain scant (Erlandson et al. 2012; Watkins
and Treisman 2012). Furthermore, the HIV-infected popu-
lation is not alone as the average age of the general popula-
tion is increasing along with the prevalence of age-
associated neurodegenerative diseases. These studies impli-
cate autophagy as a novel target for preventing and treating
HAND, AD, PD, and possibly other neurodegenerative dis-
orders. Importantly, this report suggests that young and aged
HIV patients may require unique drug regimens to combat
progression in these two distinct stages of disease.
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